iktos-secures-e15-5-million-in-funding-to-accelerate-ai-drug-discovery

French startup Iktos has secured €15.5 million in Series A funding for its AI-powered drug discovery platform. The round was co-led by M Ventures and Debiopharm Innovation Fund, with participation from Omnes Capital, and will enable Iktos to develop its technology further and expand its SaaS software offering. The company is set to launch Robotics, an end-to-end drug discovery platform that uses AI and automation of chemical synthesis to accelerate drug discovery timelines. Additionally, the company will expand its application of solutions to biological products, allowing it to offer fully integrated drug discovery services to the pharmaceutical industry. Iktos, which was founded in 2016, uses a technology platform for deep learning-based drug design that offers significant productivity gains in upstream pharmaceutical R&D.